Answering the Burning Question of How Transient Receptor Potential Vanilloid-1 Channel Antagonists Cause Unwanted Hyperthermia

SAMIR S. AYOUB, JOHN C. HUNTER, AND DANIEL L. SIMMONS
Centre for Biochemical Pharmacology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom (S.S.A.); and Department of Chemistry and Biochemistry, Brigham Young University, Provo, Utah (J.C.H., D.L.S.)

The transient receptor potential vanilloid-1 (TRPV1) channel is a nonselective cation channel expressed on the membrane of neurons that is activated by several stimuli, such as noxious heat, low pH, and vanilloid compounds such as capsaicin. In recent years, pharmaceutical companies have aggressively pursued TRPV1 antagonists to treat inflammatory and neuropathic pain, because TRPV1 is found on a subset of nociceptors sensitive to various pain stimuli, the response to which is attenuated in TRPV1 knockout mice (Caterina et al., 2000; Davis et al., 2000; Premkumar and Sikand, 2008). From a pharmaceutical standpoint, the stakes couldn’t be higher, since the worldwide analgesic market in 2010 is estimated to be $75 billion (Gharat and Szallasi, 2007).

However, as early as 1878, it was noticed that the substance responsible for the “hot” taste of red peppers, later isolated and identified as capsaicin, when introduced into the stomach, caused body temperature in dogs to fall, suggesting a role of the capsaicin-activated pathway in thermoregulation (Jancsó-Gábor et al., 1970). This hypothermic effect has now been validated over decades in numerous studies and organisms with various TRPV1 agonists termed vanilloids. Most importantly in terms of drug development, antagonism of TRPV1 by compounds of differing chemotypes has now been shown to cause serious hyperthermia in laboratory animals and in humans. This on-target side effect is not trivial, patients reaching temperatures as high as 40°C (104°F), and has created an obstacle for the development of TRPV1 antagonists as therapeutic agents (Gavva et al., 2008).

The review article by Romanovsky et al. (2009) published in this issue is the much-anticipated thorough treatment that seeks to clarify the ever-confusing question of how TRPV1 functions in thermoregulation. Romanovsky et al. (2009) provide a holistic view of TRPV1 in which it does not act as a central, hypothalamic thermosensor for regulation of deep body temperature. Rather, they present compelling evidence that TRPV1 channels function in a neural pathway that normally...
responds to tonic nonthermal signals from the viscera (Fig. 1, right). These tonic signals result in the activation of TRPV1 channels to inhibit the cold defense mechanisms and suppress core body temperature. Tonic activation of visceral TRPV1 is proposed to be modulated in vivo by endovanilloids and certain stimuli, such as low pH, to evoke changes in core body temperature. This “illogical” pathway is not involved in responding to physiological temperatures; rather, it influences core body temperature in response to “illogical” or nonthermal stimuli. Examples of these types of stimuli are the reflexive changes in brown adipose tissue metabolism that occur upon stomach distension. The details of this physiological modulation by endogenous endovanilloids or other stimulators are largely unknown.

Exogenous TRPV1 agonists and antagonists, according to Romanovsky et al. (2009), inversely influence core body temperature according to where each type of compound acts on TRPV1 receptors in the tonic neuronal pathway. Antagonists work on peripheral neurons, whereas agonists work centrally at the preoptic area (POA) of the hypothalamus. Antagonists remove the tonic “brake” on body temperature exerted by this neural pathway, resulting in hyperthermia, whereas agonists, acting centrally, decrease temperature by stimulating TRPV1 on neurons that act to suppress the cold defense mechanisms (e.g., nonshivering thermogenesis and vasoconstriction) of the body (Fig. 1). By this scheme, TRPV1 agonists and antagonists are acting on only one of a number of integrated neural pathways that the body uses to sense changes, thermal and nonthermal, in its environment rather than on a hypothetical central hypothalamic neuronal site that governs the set point for core body temperature.

From a pharmacological standpoint, this is important in determining whether the severe hyperthermic side effect of TRPV1 antagonists can be avoided as well as determining how other pharmacologically important drugs work that change core body temperature, such as acetaminophen. It has thus been proposed that the actions of acetaminophen on the thermoregulatory system (antipyresis and hypothermia), which are still poorly understood, may be mediated through activation of TRPV1. Högestätt et al. (2005) demonstrated that acetaminophen is converted to AM404, which is a hypothermic agent with potency for the activation of TRPV1 similar to that of capsaicin (De Petrocellis et al., 2000). Thus AM404 may be responsible for the hypothermic action of acetaminophen. However, less than 0.002% of acetaminophen is converted to AM404. This issue is anything but settled, and acetaminophen and other compounds may reveal additional neural target sites involved in thermoregulation.

Some readers will find the stance of Romanovsky et al. (2009) regarding the sites of action of TRPV1 agonists and antagonists to be controversial, because the authors, like other investigators, are faced with the fact that TRPV1 channels are widely distributed in the body on both neural and non-neural cells, such as mast cells, glial cells, and keratinocytes (Premkumar and Sikand, 2008). For example, TRPV1 is expressed in the terminal ends of afferent thinly myelinated A and unmyelinated C-fibers innervating many organs that include the skin, skeletal muscles, and visceral organs. In the brain, TRPV1 is also widely distributed, including, but not limited to, the thermoregulatory POA of the hypothalamus. The question, then, is which TRPV1 channels among the myriad of possibilities act to affect body temperature?

Romanovsky et al. (2009) pinpoint the site of agonist action to median preoptic nucleus neurons in the hypothalamus. They come to this conclusion based on pharmacological, neuron ablation, and desensitization studies, as well as in vitro TRPV1 analysis. Because median preoptic nucleus neurons are insensitive to temperature, they could not be hypothalamic thermosensors. Data implicating these neurons as the agonist site of action include the fact that capsaicin, the first known TRPV1 agonist, induces a hypothermic response when administered systemically. Direct administration of capsaicin into the POA at doses 25 times lower than those given systemically was found to be sufficient to induce hypothermia, strongly supporting a central site of action. More support for this argument comes from the observation that animals treated repeatedly with high doses of capsaicin or resiniferatoxin (RTX), a TRPV1 agonist, respond with desensitization of the TRPV1 channel and impairment of the hypothermic response. Specifically, rats pretreated intrahypothalamically with capsaicin demonstrated reduced sensitivity to systemically administered capsaicin to induce hypothermia due to POA neuronal death.

In contrast to agonists, the authors demonstrate that the site of TRPV1 antagonist-induced hyperthermia is not the brain, but the abdominal cavity (“viscera” in Fig. 1). To support this, they note that AMG0347 (a synthetic
TRPV1 antagonist) administered intravenously at doses of 6 and 10 µg/kg induced hyperthermia; however when administered intracerebroventricularly or intratheca
cally at a similar dose range it failed to induce hyperthermia. In addition, animals treated with 0.02 mg/kg RTX intra
eritoneally, resulting in localized intra-abdominal de
sensitized TRPV1 channels, did not develop hyperther
dia when treated with AMG0347. The localized intra
abdominal desensitization of TRPV1 is demonstrated by
changes in satiety response to cholecystokinin and
writhing response to intraperitoneal RTX with no
changes to physiological responses associated with
TRPV1 channels in other tissues such as the eyes, skin,
thoracic cavity and brain (Steiner et al., 2007). These
findings provide strong evidence for a visceral site of
hyperthermic action of TRPV1 antagonists.

This is important from a therapeutic point of view
because it allows the authors to propose a number of
strategies to dissociate the therapeutic (analgesia) ac
tion of TRPV1 antagonists from their on-target side
effect (hyperthermia). Two of these strategies have
shown some promise. These include the fact that, upon
repeated administration of antagonists, hyperthermia
attenuates whereas analgesia ensues. This strategy, of
course, exposes the patient to one or more unpleasant
rounds of hyperthermia-inducing TRPV1 antagonist
treatment before things presumably get better. They
also note that in clinical trials with AMG 517, only high
doses (10 mg) brought about subsequent attenuation of
hyperthermia (Gavva et al., 2008).

The most promising strategy, however, is based on
the fact that opening of the channel uses different gating
mechanisms based on the agonist in question. Thus,
different TRPV1 antagonists may block activation of
the channel depending on the agonist. A good example
that the authors use to illustrate this point is that capsaz
epine failed to antagonize TRPV1 when activated by
protons and has not been reported to induce hyperther
mia. It was later confirmed that an antagonist that
blocks TRPV1 activation by capsaicin and potentiates
the activation induced by protons (instead of blocking)
was likewise found to lack a hyperthermic action in rats
(where it actually induced hypothermia instead). Such
compounds include AMG8562 and AMG7905. Unfortu
nately, AMG8562 at least, is not expected to work in
humans, because it does not inhibit proton activation of
TRPV1 in rats, but it inhibits all modes of TRPV1 acti
vation in human (Lehto et al., 2008). Until these com
pounds are tested in clinical trials, whether hyperther
mia-free TRPV1 antagonists can be developed will
remain hotly debated.

REFERENCES
Caterina MJ, Leffler A, Malmberg AB, Martin WJ, Trafton J, Petersen-Zeitz KR,
Koltzenburg M, Bashbaum AI, and Julius D (2000) Impaired nociception and pain
between the ligand recognition properties of the anandamide transporter and the
VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-
like activity. PEBLS Lett 483:52–56.
Gharat L and Szallasi A (2007) Medicinal chemistry of the vanilloid (capsaicin) trpv1
Högestätt ED, Jonsson BA, Ermund A, Andersson DA, Björk H, Alexander JP,
Cravatt BF, Bashbaum AI, and Zygmont PM (2005) Conversion of acetaminophen
to the bioactive N-acetylphenolamine AM404 via fatty acid amide hydrolase-
dependent arachidonic acid conjugation in the nervous system. J Biol Chem.
280:31405–31412.
Jancsó-Gábor A, Szolcsányi J, and Jancsó N (1970) Irreversible impairment of
thermoregulation induced by capsaicin and similar pungent substances in rats and
Lehto SG, Tamir R, Deng H, Klionsky L, Kuang R, Le A, Lee D, Louis JC, Magal E,
Manning BH, et al. (2008) Antihyperalgesic effects of (E,E)-N-(2-hydroxy-2,3-
dihydr-4H-inden-4-yl)-3-(2-(piperidin-1-yl)-4-(trifluoromethyl)phenyl)-acryl-
amide (AMG8562), a novel transient receptor potential vanilloid type 1 modulator
that does not cause hyperthermia in rats. J Pharmacol Exp Ther 326:218–229.
Romanovsky AA, Almeida MC, Garami A, Steiner AA, Norman MH, Morrison SF,
Nakamura K, Burmeister JJ, and Nucci TB (2009) The transient receptor poten-
tial vanilloid-1 channel in thermoregulation: a thermosensor it is not.
Pain 151:151–163.
Steiner AA, Turek VF, Almeida MC, Garami A, Steiner AA, Norman MH, Louis JC,
et al. (2007) Nonthermal activation of transient receptor potential vanilloid-1 channels in abdominal viscera